Published • loading... • Updated
Ocular Therapeutix Eyes Q4 FDA Filing for AXPAXLI After SOL-1 Win
Summary by MarketBeat
1 Articles
1 Articles
Ocular Therapeutix Eyes Q4 FDA Filing for AXPAXLI After SOL-1 Win
Ocular Therapeutix (NASDAQ:OCUL) is preparing a fourth-quarter new drug application submission for AXPAXLI, its investigational maintenance treatment for wet age-related macular degeneration, following discussions with the U.S. Food and Drug Administration, President and Chief Executive Officer Prav
·Sioux Falls, United States
Read Full ArticleCoverage Details
Total News Sources1
Leaning Left0Leaning Right0Center1Last UpdatedBias Distribution100% Center
Bias Distribution
- 100% of the sources are Center
100% Center
C 100%
Factuality
To view factuality data please Upgrade to Premium
